Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > NASH

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Aug 17, 2021 1:27pm

113 Views

Post# 33717592

RE:NASH

More of that.

https://www.fiercepharma.com/pharma/intercept-still-sees-fda-approval-pathway-for-nash-hopeful-ocaliva-as-long-as-safety-holds

So extending data out to 18 months. That is where fda guidance went at the start of this year. I think we probably should think of THTX's 18 month decision as likely just where things are moving in NASH rather than anything specific to their drug.

Add uncertainty to the picture and RBC's Abrahams gets confused/wants clarity, sound familiar?

scarlet1967 wrote:

Despite the recent setbacks many companies still are trying to develop a drug for the condition. For instance Intercept with a drug with serious safety issues still is trying to get it approved.
Reason is NASH is multi billion dollar market with growing prevalence and unmet.

https://www.clinicaltrialsarena.com/analysis/intercept-nash/